nasdaq.com
Lilly Reports Positive Two-Year VIVID-2 Study Results For Omvoh In Crohn's Disease
Durable treatment responses matter to people with Crohn’s disease because sustained clinical remission and endoscopic improvement can mean fewer symptoms and less inflammation over time. Longer safety and durability data help patients and clinicians weigh treatment options after approval.
Adults with moderately to severely active Crohn’s disease, patients considering or already on Omvoh, gastroenterologists, and researchers following biologic treatments for IBD.
What To Know
What to know Lilly reported two-year results from the VIVID-2 open-label extension study of Omvoh in adults with moderately to severely active Crohn’s disease.
The company says most patients who were in clinical remission or had an endoscopic response at one year maintained those outcomes at two years; additional patients not in remission at year one achieved remission during year two. Safety findings were described as consistent with prior data.
The update comes after Omvoh’s FDA approval for Crohn’s disease in January 2025 (the drug was previously approved for ulcerative colitis). The study is ongoing as a long-term extension and Lilly noted plans for further regulatory submissions and pediatric/adult studies.
If you’re reading study updates as a patient, note this is an industry-reported summary of an open-label extension; it focuses on durability of response and safety over two years rather than randomized controlled comparisons.
This article is an industry/financial-news write-up summarizing company-reported results from an open-label extension (VIVID-2). Open-label extension data reflect outcomes on continuing treatment but do not replace randomized controlled trial evidence; details on study design, patient numbers, and independent peer review were not provided in this summary.
